|
Bioton SA - Comparative Business Analysis Snapshot
Business Description
Bioton SA. The Group's principal activity is manufacture of clinically important modern drugs, including recombined human insulin and its pharmaceutical forms, preparations from the cephalosporine, aminoglycoside and macrolide groups. The Group operates in four segments: Insulin and Derivatives, Antibiotics, Growth Hormone and Other. The Group closely co-operates with the Institute of Biotechnology and Antibiotics, which conducts the research of drugs using chemical synthesis and biosynthesis based on genetic engineering methods, and develops technologies of drug manufacturing. In 2008, the Group acquired MJ BIOTON Life Sciences Ltd (Cyprus) and Trice SA (Luxembourg). The Group operates in Poland, Cyprus and Singapore.
Competitor Analysis
This analysis compares Bioton SA with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
